Bioenvision
Engages in the acquisition, development and marketing of compounds and technologies primarily for the treatment of cancer.
Launch date
Employees
Market cap
-
Enterprise valuation
€314m (Public information from May 2007)
New York City New York (HQ)
Date | Investors | Amount | Round |
---|---|---|---|
$7.4m | Early VC | ||
$345m Valuation: $345m | Acquisition | ||
Total Funding | €6.7m |
Recent News about Bioenvision
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.